No Data
No Data
Alzheimer's Drug Study Yields Mixed Results. Wall Street Still Likes Axsome
Axsome Therapeutics Price Target Cut to $122.00/Share From $124.00 by Mizuho
Axsome Therapeutics Is Maintained at Outperform by Mizuho
Express News | Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $122
Axsome Therapeutics Mixed Alzheimer's Disease Agitation Data Disappoints but Approvability Seen Likely, Mizuho Says
Leerink Partners Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $110